PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis

European Journal of Cancer

Volumn 65, Issue , 2016, Pages 52-60

  Hecht, Markus ^a   Büttner Herold, Maike ^a   Erlenbach Wünsch, Katharina ^a   Haderlein, Marlen ^a   Croner, Roland ^a   Grützmann, Robert ^a   Hartmann, Arndt ^a   Fietkau, Rainer ^a   Distel, Luitpold V ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adenocarcinoma; Cancer; Nivolumab; PD 1; PD L1; Pembrolizumab; Radiation; Radiochemotherapy; Radiotherapy; Rectal

Indexed keywords

FLUOROURACIL; OXALIPLATIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ADENOCARCINOMA; AGED; CHEMORADIOTHERAPY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; RECTAL NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CHEMORADIOTHERAPY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECTAL NEOPLASMS; UP-REGULATION;

EID: 84978955312     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.06.015     Document Type: Article

References (18)

1. [1] Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med 373:2 (2015), 123–135.
2. [2] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
3. [3] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:26 (2015), 2509–2520.
4. [4] Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Calio, A., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 10(6), 2015, e0130142.
5. [5] Reichl, B., Block, A., Schafer, U., Bert, C., Muller, R., Jung, H., et al. DEGRO practical guidelines for radiotherapy of non-malignant disorders: Part I: physical principles, radiobiological mechanisms, and radiogenic risk. Strahlenther Onkol 191:9 (2015), 701–709.
6. [6] Shahabi, V., Postow, M.A., Tuck, D., Wolchok, J.D., Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol 38:1 (2015), 90–97.
7. [7] Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:2 (2014), 687–695.
8. [8] Dovedi, S.J., Adlard, A.L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E.J., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74:19 (2014), 5458–5468.
9. [9] Zeng, J., See, A.P., Phallen, J., Jackson, C.M., Belcaid, Z., Ruzevick, J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:2 (2013), 343–349.
10. [10] Lim, S.H., Hong, M., Ahn, S., Choi, Y.L., Kim, K.M., Oh, D., et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer 52 (2015), 1–9.
11. [11] McCoy, M.J., Hemmings, C., Miller, T.J., Austin, S.J., Bulsara, M.K., Zeps, N., et al. Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer 113:12 (2015), 1677–1686.
12. [12] Selzer, E., Grah, A., Heiduschka, G., Kornek, G., Thurnher, D., Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: comparative analysis of inflammation-based prognostic scoring systems. Strahlenther Onkol 191:6 (2015), 486–494.
13. [13] Wu, P., Wu, D., Li, L., Chai, Y., Huang, J., PD-L1 and survival in solid tumors: a meta-analysis. PLoS One, 10(6), 2015, e0131403.
14. [14] Droeser, R.A., Hirt, C., Viehl, C.T., Frey, D.M., Nebiker, C., Huber, X., et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49:9 (2013), 2233–2242.
15. [15] Liang, M., Li, J., Wang, D., Li, S., Sun, Y., Sun, T., et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province. Tumour Biol 35:1 (2014), 55–60.
16. [16] Ahmed, K.A., Stallworth, D.G., Kim, Y., Johnstone, P.A., Harrison, L.B., Caudell, J.J., et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27:3 (2016), 434–441.
17. [17] Zhang, Y., Kang, S., Shen, J., He, J., Jiang, L., Wang, W., et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore), 94(6), 2015, e515.
18. [18] Zlobec, I., Lugli, A., Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol 15:47 (2009), 5898–5906.